EPS: As of FY2025 Q1, the actual value is USD 38.62.

Segment Revenue

• The company has not generated any revenue to date.

Operational Metrics

• Net Income (Loss): For the three months ended March 31, 2025, the company reported a net income of $1,928,834, compared to a net loss of - $982,386 for the same period in 2024.
• Research and Development Expenses: Decreased to $82,016 in 2025 from $197,439 in 2024, a reduction of $115,423 or 58%.
• General and Administrative Expenses: Increased to $1,939,753 in 2025 from $1,646,613 in 2024, an increase of $293,140 or 18%.

Cash Flow

• Net Cash Used in Operating Activities: - $2,450,564 for the three months ended March 31, 2025, compared to - $1,889,315 for the same period in 2024.
• Net Cash Used in Investing Activities: - $473,658 in 2025, compared to - $2,852 in 2024.
• Net Cash Provided by Financing Activities: $13,953,031 in 2025, compared to $396 in 2024.

Unique Metrics

• Warrant Liability: As of March 31, 2025, the warrant liability was $7,781,658, compared to $98,913 as of December 31, 2024.

Future Outlook and Strategy

• Core Business Focus: The company is committed to driving revenue growth from Securegard and Sologard projects in 2025, with production on track for a transition to revenue in the second half of 2025.
• Non-Core Business: The company continues to work towards amending the Asset Purchase Agreement with Nephron and InjectEZ, LLC, with the closing contingent on obtaining further amendments and necessary financing.